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Abstract
Regeneration of injured skeletal muscles is affected by fibrosis, which can be improved by
the administration of angiotensin II (AngII) receptor (ATR) blockers in normotensive animals.
However, the role of ATR in skeletal muscle fibrosis in hypertensive organisms has not been
investigated yet. The tibialis anterior (TA) muscle of spontaneously hypertensive (SHR) and
Wistar rats (WR) were lacerated and a lentivector encoding a microRNA targeting AngII
receptor type 1 (At1) (Lv-mirAT1a) or control (Lv-mirCTL) was injected. The TA muscles
were collected after 30 days to evaluate fibrosis by histology and gene expression by real-
time quantitative PCR (RT-qPCR) and Western blot. SHR’s myoblasts were analyzed by
RT-qPCR, 48 h after transduction. In the SHR’s TA, AT1 protein expression was 23.5-fold
higher than in WR without injury, but no difference was observed in the angiotensin II recep-
tor type 2 (AT2) protein expression. TA laceration followed by suture (LS) produced fibrosis
in the SHR (23.3±8.5%) and WR (7.9±1.5%). Lv-mirAT1 treatment decreased At1 gene
expression in 50% and reduced fibrosis to 7% 30 days after. RT-qPCR showed that reduc-
tion in At1 expression is due to downregulation of the At1a but not of the At1b. RT-qPCR of
myoblasts from SHR transduced with Lv-mirAT1a showed downregulation of the Tgf-b1,
Tgf-b2, Smad3, Col1a1, and Col3a1 genes by mirAT1a. In vivo and in vitro studies indicate
that hypertension overproduces skeletal muscle fibrosis, and AngII-AT1a signaling is the
main pathway of fibrosis in SHR. Moreover, muscle fibrosis can be treated specifically by in
loco injection of Lv-mirAT1a without affecting other organs.
Introduction
Skeletal muscles weight about 33–40% of total body weight of non-obese men and women,
being responsible for posture and voluntary movements [1]. Muscle injury can cause muscle
contracture, atrophy, and fibrotic scar tissue, which can affect physical movements [2,3].
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Complete muscle recovery after a serious injury is usually affected by the establishment of a
fibrotic scar tissue at the site of injury. Sportsmen who demand highly efficient muscle func-
tioning can suffer with even small fibrosis, and recurrent injuries can occur at the same site
during physical exercises [4,5].
Fibrosis is part of the final step of muscle recovery and is characterized by intense synthesis
of extracellular matrix (ECM) proteins by myofibroblasts, which results in the formation of
connective tissue scar [6]. In cases of severe muscle injury, fibrogenesis is exacerbated and
results in the formation of a dense scar, besides irregular and malfunctioning tissue [3,7].
Therapy based on anti-inflammatory drugs, ice, and rest have limited efficacy in preventing or
treating muscle fibrosis after injury [8,9].
Several studies have shown that hypertension promotes fibrosis, and angiotensin II (AngII)
receptor type 1 (AT1) is the key factor in hypertension and fibrosis [10,11]. Reduction of fibro-
sis by AT1 blockers is an important evidence of the fibrotic activity of AngII-AT1[12–14].
Even in the chronic muscular genetic diseases, such as Marfan syndrome and Duchenne mus-
cular dystrophy, the AT1 antagonist losartan was able to reduce fibrosis, improving skeletal
muscle regeneration [13].
TGF-β1 is a pleiotropic factor that orchestrate various cell activities. It promotes the nega-
tive proliferation of myeloid, epithelial, and lymphoid tumor cells [15,16], but it also stimulates
fibroblast proliferation [17] and ECM synthesis in myofibroblasts [18]. Due to these last activi-
ties, TGF-β1 is considered the most important fibrotic factor [19,20]. It is known that
AngII-AT1 and TGF-β1 signaling cross-talk activates Smad2/3 and upregulates the fibrogenic
factor connective tissue growth factor (CTGF) and collagen I expression [21]. However, the
pro-fibrotic AngII-AT1 activity can also occur via TGF-β1 in an independent manner [22,23].
According to the World Health Organization (http://www.who.int), there are about 1 bil-
lion hypertensive people in the world. In addition, hypertension is one of the most important
risk factors for cardiovascular diseases, which affect heart, brain, peripheral limbs, and other
organs [24,25]. Although there are several significant numbers of studies showing the effect of
AngII-AT1 signaling in skeletal muscle fibrosis, the knowledge about this signaling in skeletal
muscles of hypertensive organisms is not clear [14,26–28].
The spontaneously hypertensive rat (SHR) has been largely used to study physiology and
pathophysiology related to human hypertension (over 13,000 Medline references were found
using both “SHR” and “hypertension” words) due to the genetic predisposition to hyperten-
sion and age dependence to manifest hypertension, as occurs in humans [29]. The spontane-
ous cardiac fibrosis is a major complication of hypertension in SHR, and the development of
fibrous tissue is related to overexpression of TGF-β1, which is stimulated by AngII [30–32].
The AT1 blockers or angiotensin converting enzyme (ACE) inhibitors have been successfully
used to reduce hypertrophy and cardiac fibrosis in this model [33–35]. Although the AT1
blocker losartan showed significant benefits in the treatment of muscle fibrosis, this medica-
tion has a systemic action and can cause several adverse effects [36–38]. Therefore, the search
for a localized therapy for patients with muscle injury and fibrosis is necessary.
Here, we report a study on the relationship between fibrogenesis and AT1 in the skeletal
muscle of SHR after a severe injury, using the normotensive Wistar rat (WR) as a control. To
establish a deep injury in the skeletal muscle, we chose laceration followed by suture because it
is a common practice among orthopedists to treat deep muscle injury, which can occur among
sportsmen and patients who suffered of vehicle accidents. In addition, as it was commented by
Bedair et al [14], laceration is a highly reproducible muscle injury model, its histopathology is
very similar to that observed in strain injury patterns, and any treatment benefits seen in this
model would likely bring equal or greater benefit in less severe strain injuries. We hypothe-
sized that the skeletal muscle of SHR should express more ATR and, should thus produce
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more fibrotic tissue after injury. Down-regulation of the AT1 receptor in the SHR muscle by
miRNA should reduce fibrosis and promote better muscle regeneration. This strategy may
provide a useful in loco treatment of patients with deep muscle injuries.
Materials and methods
Animals and muscle laceration
The SHR were obtained from the animal facility of the Institute of Biomedical Sciences, Uni-
versity of São Paulo (USP), and WR were obtained from the National Institute of Pharmacol-
ogy, Federal University of São Paulo (UNIFESP). All rats (35 SHR and 15 WR) were 16-week-
old males (weight: 300–350 g). All procedures involving animals were performed only after the
project protocol received approval by the Research Ethics Committee of UNIFESP (Approval
number: 0347/12). The completed ARRIVE (Animal Research: Reporting In Vivo Experi-
ments) Checklist is in S1 File.
For muscle laceration, SHR and WR were initially anesthetized with intraperitoneal (ip)
injection of ketamine (40 mg/kg) and xylazine (20 mg/kg). Muscles were surgically lacerated
as previously described [39], with some modifications. Briefly, the tibialis anterior (TA) muscle
from both legs were exposed and transversely cut with a scissor in the middle of the muscle
(Fig 1A). The muscles were sutured (laceration-suture group, LS) or not (laceration group, L)
after the injury. In the LS group, a PDSII 5–0 suture (Ethicon; NJ, USA) was placed at the
medial edge of the lacerated site. After laceration, the skin was closed with black silk 4–0 suture
(Ethicon). Four weeks after laceration, all animals were euthanized to evaluate muscle healing
and fibrosis. Five muscles from each group were evaluated by histology and other five muscles
were evaluated by real-time quantitative PCR (RT-qPCR) and Western blot.
Primary muscle cell culture from SHR and WR
Primary muscle cells were obtained by enzymatic disaggregation of leg muscle from 1-day-old
SHR (CEDEME animal facility, UNIFESP) or WR (INFAR animal facility, UNIFESP) and cul-
tured as previously described previously [40–42]. Eight rats were used in this study. Isolated
cells were then suspended in Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies;
NY, USA) with 10% fetal bovine serum (FBS; Life Technologies), 10% horse serum (Sigma
Chemical Co.; MO, USA), 0.5% chick embryo extract (United States Biological; MA, USA),
penicillin/streptomycin (100 U/mL; Life technologies) and 2 mM L-glutamine (Life technolo-
gies), and maintained at 37˚C with 5% CO2. Cells were then plated in collagen-coated flasks.
Two hours after plating, the supernatant was removed from the flask and replated in a fresh
collagen-coated flask. Within 2-h incubation, mostly fibroblasts adhered to the collagen coat.
The serial replating of non-adherent cells was repeated daily for 4 days to establish a primary
myoblast cell culture [40,41]. The rat skeletal muscle cell line L6 (ATCC; VA, USA) was used
as a control.
AngII effect in primary muscle cells
SHR and WR primary muscle cells were seeded on a 24-well plate (3x104 cells/well) and 24
hours later AngII (kindly donated by Dr. Julie Bossuyt, University of California, Davis) was
added to a final concentration of 100 nM/well [43,44]. After 24 hours, the total RNA was
extracted and genes were quantified following methods described in the Gene expression anal-
ysis by Real-time quantitative PCR (RT-qPCR) section.
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Lentivector construction, production, and transduction
The mirAT1a (micro RNA to AT1a receptor) and mirCTL (micro RNA control) sequences are
the same as those from Fan et al [45]. They were obtained from GenScript (NJ, USA) and were
cloned into the pUC57 vector. The mirAT1a and mirCTL sequences were removed from the
Fig 1. Rat muscle injury model. (A) Schematic design of the rat muscle injury model. The tibialis anterior (TA) muscle was cut in
the middle (laceration group: L) and sutured (laceration-suture group: LS) or not. Four weeks after this procedure, the muscle was
excised and cut longitudinally to histology. (B) Macroscopic images of the TA muscle from SHR and WR (scale bar = 1 cm). (C)
TA muscle weight comparison among groups Representative micrographs of sections stained with PR or HE (scale bar = 50 μm).
(D) Fibrotic areas quantified using images from Fig 1D (E). * indicates statistically significant differences (p<0.05) when animals
of the same species of rats were compared with subjected to different laceration processes. # indicates statistically significant
differences (p<0.05) when animals of different species were compared for subjected to the same laceration process. Values
represent mean ± standard deviation. n = 5 rats per group. TA: tibialis anterior; EDL: extensor digitorum longus; SHR:
spontaneously hypertensive rat; WR: Wistar rat; CTL: control group (without injury); PR: Picrosirius Red; HE: hematoxylin-eosin.
https://doi.org/10.1371/journal.pone.0186719.g001
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pUC57 vector using MluI/ClaI and cloned into the pLVTHM vector (Addgene; MA, USA),
which was previously treated with the same enzymes. These vectors were named as pLv-mir-
AT1a and pLv-mirCTL. All plasmids were amplified using the Plasmid Midi Kit1 (Qiagen;
Hilden, Germany) and sequenced in the 3100 Avant Genetic Analyzer (Life Technologies).
The lentivectors were produced using the plasmids psPAX2 (Addgene), M5 (Express
VSV-G; this vector was kindly provided by Prof. D.von Laer; Chemotherapeutisches For-
schungsinstitut, Georg-Speyer-Haus). Lentivector production, concentration, and titration
were performed following the protocol established by Naldini et al [46]. In brief, lentivectors
were produced by transfection of human embryonic kidney cells (HEK-293T), which were cul-
tured (37˚C; 5% CO2) in DMEM (Life Technologies) with 10% FBS (Life Technologies), peni-
cillin/streptomycin (100 U/mL; Life technologies), and 2 mM L-glutamine (Life technologies).
The culture supernatant was collected after 2 and 3 days, and filtered through a 0.45-μm pore
diameter (Millipore; NY, USA) syringe filter, and concentrated (37,000 xg; 4˚C; 2 h) in a Sor-
vall (5C plus model; Thermo Fisher Scientific; MA, USA) centrifuge. Lentivectors produced
with pLv-mirAT1a and pLv-mirCTL were named as Lv-mirAT1a and Lv-mirCTL,
respectively.
To determine the viral titer, which was expressed as transducing units (TU) per mL, HEK-
293T cells were transduced with different concentrations of lentiviral vectors in the presence
of Polybrene (8 μg/mL; Sigma). After 3 days, the HEK-293T cells expressing GFP were counted
(>10,000 events analyzed) using a FACScan (Becton Dickinson, BD; CA, USA) cytometer and
the data was analyzed using the FlowJo (TreeStar Inc.; OR, USA) software. The titer is given by
GFP positive cells (%) X total number of cells on the day of transduction / volume of virus.
For transduction of L6 and rat primary muscle cells from SHR (passage 4), these cells were
seeded on a 6-well plate at 70% confluence, with DMEM supplemented with 10% FBS. After
24 h, the medium was replaced with a fresh one containing Polybrene (8 μg/mL; Sigma), and
Lv-mirAT1a or Lv-mirCTL vectors were added to the media with multiplicity of infection
(MOI) to transduce L6 (MOI = 10) or rat primary muscle cells (MOI = 50). After 24 h, all
media were replaced with fresh ones.
Gene therapy
The SHR and WR were anesthetized with ip injection of ketamine (40 mg/kg) and xylazine (20
mg/kg), and muscles were lacerated as described above. Soon after laceration, 1.2 x 107 TU of
Lv-mirAT1a or Lv-mirCTL in DMEM (100 μL) were injected in each TA muscle. Four weeks
after the treatment, the muscles were removed for histology, gene, and protein expression
analysis.
Histological analysis
After the TA muscles were excised, they were weighted and fixed in formaldehyde (10%; 24 h).
Next, the muscles were cut (Fig 1A), dehydrated, and embedded in paraffin. Four-micrometer
sections were obtained and stained with hematoxylin-eosin (HE) or Picrosirius Red (PR).
Digital images were acquired using a microscope, and 20 fields per slide were analyzed
using the Image Pro Plus (Media Cybernetics, Inc.; MD, USA) software. Fibrotic areas were
expressed in percentage of PR stained area per total injured area, constituted by the middle
portion of TA where the injury was established.
Gene expression analysis by real-time quantitative PCR (RT-qPCR)
Total RNA from TA muscles, heart, primary culture of muscle cells, or L6 cells were extracted
with the Trizol reagent (Life Technologies) and treated with DNAse I (Invitrogen).
Skeletal muscle fibrosis of spontaneously hypertensive rat
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Complementary DNA (cDNA) was synthetized using RNA (1μg) with the High-Capacity
cDNA Reverse Transcription (Life Technologies) kit. The real-time quantitative PCR RT-
qPCR was performed using the QuantiFast Probe Assay (Qiagen) kit or SYBR green kit (Qia-
gen) in the Rotor Gene-Q (Qiagen). The QuantiFast Probe Assay kit was used to quantify rat
Angiotensin II receptor, type 1a (Agtr1a; Qiagen, Catalog number (Cat.N˚): QF00333130),
Angiotensin II receptor, type 1b (Agtr1b; Qiagen, Cat.N˚: QF00146503), Angiotensin II recep-
tor, type 2 (Agtr2; Qiagen, Cat.N˚: QF00267043) and the control gene peptidylprolyl isomerase
A (Ppia; Qiagen, Cat.N˚: QF00531300). The SYBR green kit was used to quantify the expres-
sion of the following genes: Transforming growth factor, beta 1 (Tgfb1); collagen, type I, alpha
1 (Col1a1); collagen, type III, alpha 1 (Col3a1); connective tissue growth factor (Ctgf); SMAD
family member 2 (Smad2); SMAD family member 3 (Smad3); transforming growth factor,
beta receptor 1 (Tgfbr1); transforming growth factor, beta receptor 2 (Tgfbr2); and 18S ribo-
somal RNA (Rn18S). The primer sequences used in the real-time RT-qPCR were described in
the S1 Table. The relative gene expression was calculated by the 2-ΔΔCT method. Changes in
mRNA expression were expressed as fold-changes relative to a control, which was specified in
the figure legends.
Gene expression analysis by Reverse Transcription-PCR (RT-PCR)
The RT-PCR was performed using the Platinum TAQ DNA polymerase (Life Technologies)
kit according to the manufacturer’s instructions. The genes evaluated by the RT-PCR were as
follows: myogenic factor 5 (Myf5), myogenic regulatory factor (Myod), and desmin (Des). The
primer sequences were obtained using the Primer 3 (University of Massachusetts, USA) soft-
ware, and the sequences are listed in the S1 Table.
Protein analysis
Samples from the TA muscle (SHR: 600–700 mg; WR: 800–900 mg) or heart (1.0–1.2 mg)
were excised and crushed in the Ultra-Turrax (IKA; Campinas, Brazil) tissue triturator with
extraction buffer (50 mM Tris, 150 mM NaCl, 0.05% deoxycholate, 1% NP-40, 1.0 mM EDTA,
0.1% SDS; pH 8.0; 1.0 mL) containing phenylmethylsulfonyl fluoride (PMSF; 1/100, v/v). The
samples were centrifuged (8000 xg; 4˚C; 5 min) after the supernatant was collected and stored
(-80˚C) until analysis. Total protein content was quantified using the Bio-Rad DC protein
assay (Bio-Rad; CA, USA) kit. The samples were incubated (95˚C; 5 min) with sample buffer
(375 mM Tris/HCl, 120 mM EDTA, 12% SDS, 1.0 mg/mL bromophenol blue, 40% glycerol;
pH 6.8).
For the western blot analysis, protein aliquots (50 μg) from each sample were mixed with a
loading buffer (375 mM Tris-HCl, 120 mM EDTA, 12% SDS, 1.0 mg/mL bromophenol blue,
40% glycerol; pH 6.8) and loaded on 12% SDS-PAGE gel for electrophoresis (100 V; 2 h). After
this run was completed, the gel contents were electrotransferred (100 V; 1 h; RT) onto a nitro-
cellulose membrane (0.45-μm pore size; Hybond ECL; Amersham Biosciences; Freiburg, Ger-
many). The membrane was blocked (2 h; RT) in Tris-buffered saline (TBS; 10.0 mM Tris, 150
mM NaCl; pH 7.5) containing Tween 20 (TBS-T; 0.2%) and nonfat dry milk (5%). Next, the
membranes were incubated (4˚C; overnight) with primary antibodies in nonfat dry milk (2%).
The antibodies were as follows: anti-AT1 (Santa Cruz Biotechnology; TX, USA; mouse mono-
clonal antibody; Cat. No. sc-81671; 1:200 dilution), anti-AT2 (Santa Cruz Biotechnology; rab-
bit polyclonal antibody; Cat. No. sc-9040; 1:200 dilution), or anti-ß actin (Fermentas; rabbit
polyclonal antibody; Cat. No. RB-9421; 1:1000 dilution). The membranes were washed with
TBS-T and incubated (2 h; RT) with peroxide-conjugated secondary antibody (Pierce Biotech-
nology; IL, USA) containing nonfat dry milk (2%), washed with TBS-T, and incubated (5 min)
Skeletal muscle fibrosis of spontaneously hypertensive rat
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with Western Lightning1 Plus-ECL (PerkinElmer; MA, USA). The labeled bands were cap-
tured in the Alliance 4.7, (Uvitec; Cambridge, UK) scan. Membranes were stripped and rela-
beled with anti-ß-actin antibody to capture the bands again. The pixels of each band were
measured using the Image J (v. 1.47; NIH; MD, USA) software.
Statistical analysis
All statistical analyses were performed using Student t-tests (two-tail comparisons) or one-way
analysis of variance (ANOVA) with post hoc Bonferroni’s test using Prism 6 software (Graph-
pad; CA, USA). Differences between conditions were considered significant if P < 0.05.
Results
Quantitative histological analysis of muscle fibrosis after laceration
To study the relationship between hypertension and fibrosis after muscle injury, two muscle
injury methods were first compared: Laceration (L) and Laceration followed by Suture (LS)
(Fig 1A). Four weeks after the L and LS procedures were performed in SHR and WR, the mus-
cles were isolated for analyses. Macroscopic analysis showed that animals in the L group exhib-
ited a bigger injured area as compared to those in the LS group (Fig 1B). The TA muscles from
WR were 18.2% heavier than those from SHR (Fig 1C). Laceration caused a significant (15%)
decrease in the TA muscle weight in the SHR/L group as compared to that in the SHR/CTL
group, however, in the WR/L group the TA muscle weight was not significantly different in
comparison to the non-lacerated group WR/CTL (Fig 1C). Tissue fibrosis, as assessed by PR
staining, showed that fibrosis was clearly established after four weeks in both injury models.
The laceration area was characterized by an intense reddish staining (Fig 1D). The cells in the
scar were more disorganized in animals of the L group as compared to those in animals of the
LS group. The animals in the SHR/LS group showed a significant increase in the fibrotic area
as compared to those in the WR/LS group (Fig 1E). However, no difference was observed in
the fibrotic area between the LS and L groups, within the WR group.
Expression of AngII receptors in the skeletal and cardiac muscles of
hypertensive and normotensive rats
The expression of AT1 and AT2 receptor proteins in the TA and heart muscles from animals
of the of the SHR and WR groups without injury was quantified by Western blot analysis (Fig
2A) to correlate increase in fibrosis in animals of the SHR group with expression of AT1 recep-
tors. As compared to animals of the WR group, those in the SHR group showed a much higher
AT1 expression in the TA muscle (25-fold) and heart (2.4-fold). Regarding the AT2 receptor,
no gene or protein expression was detected in the SHR and WR hearts. In the TA muscle, the
AT2 receptor gene expression in the WR group was about 2-fold higher than SHR, however
no difference was observed between SHR and WR groups in terms of protein.
We also compared gene expression of AngII receptors in the TA muscle and heart of ani-
mals of the SHR and WR groups by RT-qPCR (Fig 2B). In the TA muscle, animals of the WR
group showed a significantly higher expression of Agtr1a (1.4-fold) in comparison to those of
the SHR group. However, expression of Agtr1b in animals of the SHR group expressed 2.4-fold
higher than in those of the WR group. Therefore, the higher expression of AT1 receptor pro-
tein by animals of the SHR group should be of the Agtr1b gene expression. On the other side,
Agtr2 gene expression in animals of the WR group was higher (5.6-fold).
Skeletal muscle fibrosis of spontaneously hypertensive rat
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Fig 2. Expression of AngII receptors in the skeletal and cardiac muscles. (A) The AT1 and AT2
receptors in the TA and heart muscles from animals of the SHR and WR groups were quantified by Western
Blot analysis. Band intensities were quantified by the Image J program and the ATR/β-actin ratios were
plotted (n = 3 rats per group). In the heart, AT2 receptor expression was not detected in both rat strains. (B)
Expression of the Agtr1a, Agtr1b, and Agtr2 genes in the TA and heart muscles from animals of the SHR and
WR groups was quantified by RT-qPCR (n = 5 rats per group). Expression of the Agtr1b and Agtr2 genes was
not detected in the heart from both rat strains. * p<0.05. TA: tibialis anterior. SHR: spontaneously
hypertensive rat. WR: Wistar rat.
https://doi.org/10.1371/journal.pone.0186719.g002
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In the heart, no difference was observed in the Agtr1a gene expression between animals of
the SHR and WR groups (Fig 2B). The Agtr1b gene was expressed only in animals of the WR
group, and the Agtr2 gene was not expressed in any of the rats.
Fibrogenic gene expression profile in SHR and WR myoblasts after
treatment with AngII
We investigated the fibrotic effect of AngII in SHR and WR myoblasts by RT-qPCR. AngII
upregulated the fibrogenic genes Col1a1, Col1a3, TGFbr1 and Smad3 on SHR cells (Fig 3A),
whereas only Tgfbr1and Smad3 were upregulated on WR cells (Fig 3B). Smad2 was downregu-
lated on both cells in the presence of AngII (Fig 3A and 3B).
Down-regulation of the AT1a receptor reduces fibrosis in the SHR
skeletal muscle
Initially, the efficiency of lentivectors to down-regulate the Agtr1a gene was assessed in rat
myoblast L6 cells, which express the Agtr1a gene normally [47]. Lv-mirAT1a transduced L6
cells had a reduction in Agtr1a mRNA expression in comparison with non-transduced (91.0%)
or transduced (88.5%) Lv-mirCTL (Fig 4A), showing high knockdown efficacy. No statistical
difference between non-transduced and transduced with Lv-mirCTL groups was observed.
To assess the effect of Lv-mirAT1a in fibrosis, this lentivector was injected just after lacera-
tion and the TA muscles were analyzed four weeks after the treatment. No significant differ-
ences in muscle weight were observed among groups (Fig 4B). In histology, the injured rats or
the treated with Lv-mirCTL showed an intense PR staining in a large area, whereas the group
treated with Lv-mirAT1a showed a less stained area and a pattern similar to that of non-
injured muscle (Fig 4C and 4D). Fibrosis was reduced after treatment with Lv-miAT1a, in
comparison with the groups injured (16%) or treated (18%) with Lv-mirCTL (Fig 4D). In addi-
tion, muscle architecture of Lv-mirAT1a rats was more similar to that of non-injured rats,
which was very different from the irregular muscle architecture as observed in rats injured or
treated with Lv-mirCTL (Fig 4C).
No difference was observed among groups in AT1 receptor protein expression (Fig 4E).
However, a significant reduction (53%) was observed in Agtr1a mRNA expression in the
group treated with Lv-mirAT1a in comparison with that one of the non-injured group (Fig
4F). No difference was observed in the Agtr1b and Agtr2 mRNA expressions between groups
(Fig 4G and 4H).
Gene expression analysis of myoblast primary culture after treatment
with Lv-mirAT1a
Finally, to investigate the genes regulated by the AT1a receptor, we established a primary cul-
ture of myoblasts from SHR neonates and the expression of myogenic markers (Myod, Des,
and Myf5) was evaluated by RT-qPCR in different passages, using rat myoblast cell line L6 as a
positive control. These cells were positive for the myogenic genes until passage 6 (Fig 5A).
These cells were then transduced with Lv-mirAT1a, and the gene expression profile was
analyzed 48 h later (Fig 5B). The Agtr1a expression was reduced (50%) after transduction with
Lv-mirAT1a as compared to the animals of the non-transduced group. In contrast, Agtr1b
expression was increased after transduction with Lv-mirAT1a. Regarding Agtr2, no significant
difference was observed between groups.
The Tgfb1,Tgfbr2,Col1a1, Col3a1, and Smad3 genes related to fibrosis were down-regulated
after transduction with Lv-mirAT1a (Fig 5B). The Tgfbr1and Smad2 genes were also down-
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regulated, but the variations were not statistically significant. The Ctgf gene was the only one
up-regulated after transduction with Lv-mirAT1a.
Discussion
Angiotensin II plays a central role in blood pressure control via AT1, also binding to AT2 with
similar affinity. However, several studies suggest that AT2 can antagonize AT1-mediated activ-
ities, in addition to having activities not related to AT1 signaling [48]. In rats, there are two
AT1, AT1a, and AT1b subtypes, which have similar affinity for AngII. However, studies with
AT1a and AT1b KO mice show that the block of AT1a gene affects much more blood pressure
than of AT1b, showing the importance of AT1a in the blood control than AT1b [49,50]. These
genes are expressed differently in tissues [51]. Since the ATR distribution in rat tissues is vari-
able, we first investigated the expression pattern of angiotensin receptors in the skeletal muscle,
using the heart as an experimental control due to the availability of data on angiotensin recep-
tor gene expression in this tissue [52–54].
Our gene expression data show higher AT1 expression in the heart and the skeletal muscle
of SHR as compared to WR (Fig 2) and absence of AT2 expression in the heart of both adult
rats, which explains in parts the spontaneous hypertension in SHR and AT1 specificity in the
heart. The AT2 receptor is highly expressed during embryogenesis, but such expression drops
down after birth, and its expression is maintained after birth only in some tissues [55]. In addi-
tion, its expression can vary with age and pathophysiological conditions, thus leaving the liter-
ature data apparently inconsistent. For example: AT2 expression was seen in the heart of rat
Fig 3. Fibrogenic gene expression profile in SHR and WR myoblasts after treatment with AngII.
Expression of fibrogenic genes in primary culture of SHR (A) or WR (B) myoblasts (passage 4) by RT-qPCR,
24 h after treatment with AngII (100 nM). n = 6 per group. Bars represent mean and standard deviation. *
p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
https://doi.org/10.1371/journal.pone.0186719.g003
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Fig 4. Effect of Lv-mirAT1a on laceration-injured skeletal muscle. (A) The L6 myogenic cell line was
transduced with the Lv-mirAT1a or Lv-mirCTL lentivectors (MOI = 10), and the AT1a gene expression was
evaluated 48 h later by RT-qPCR. (B) Lentivectors were injected into the TA muscle from SHR soon after LS
lesion. Later (30 days), the animals were euthanized for TA muscle weight quantification, (C) histology (scale
bar = 100 μm), (D) determination of the fibrotic area using data from Fig B, (E) expression of the AT1 protein
gene by Western blot analysis, and (F) expression of the Agtr1a, (G) Agtr1b and (H) Agtr2 genes by RT-qPCR
analysis. n = 5 rats per group. Values represent mean and standard deviation. TA: Tibialis anterior; SHR:
spontaneously hypertensive rat; CTL: SHR without injury; PR: Picrosirius Red; HE: hematoxylin-eosin stain; *
p<0.05.
https://doi.org/10.1371/journal.pone.0186719.g004
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Fig 5. Gene expression analysis of myoblasts from SHR after treatment with Lv-mirAT1a. (A)
Expression of myogenic genes in primary culture of SHR myoblasts from passages 2, 4, and 6. Cell line L6
was used as a control. (B) SHR myoblasts (passage 4) were transduced with the Lv-mirAT1a or Lv-mirCTL
lentivectors, and gene expression was analyzed 48 h later by RT-qPCR. n = 3 rats per group. Bars represent
mean and standard deviation. * p<0.05.
https://doi.org/10.1371/journal.pone.0186719.g005
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fetus by immunohistology, and its expression still could be detected 4 weeks after birth [56]; in
addition, very low level of AT2 expression was detected by RT-PCR in the aorta of SHR, which
increased 2-fold after long-term treatment with losartan [57]. Therefore, the absence of AT2
expression in the heart of 16-week old SHR and WR, as seen by two very sensitive methods
(RT-qPCR and western blot), is not contradictory to other data but reinforce the idea that AT2
expression decreases with age in the heart of healthy rats.
Another significant difference between the heart and TA muscles of SHR is that AT1a is the
unique form found in the heart, whereas presence of AT1b is about 3-fold higher than AT1a in
the TA. As was commented above, AT1a is the main regulator of arterial pressure and AT1b
contributes minimally [49,50], which is why the application of a miRNA specific to AT1a sig-
nificantly decreased fibrosis, even though the expression of AT1b is much higher than AT1a in
the TA muscle. Fibrosis reduction after AT1a knock-down is evident (Fig 4D and 4F), and the
total amount of AT1 protein found 30 days after treatment with Lv-mirAT1a had the lowest
level in comparison to the control groups (Fig 4E), although it was not significant statistically.
As AT1 antibody does not distinguish between two AT1 subtypes, the AT1 band shown in the
Fig 4E is the sum of AT1a and AT1b protein concentration. This fact should be the cause of a
less impressive decrease of AT1 protein expression than its gene expression.
The larger extension of fibrosis as observed in SHR after laceration in comparison with WR
(Fig 1D and 1E) and fibrosis reduction after treatment with Lv-mirAT1a (Fig 4D and 4F) were
the first evidence of correlation between fibrosis and hypertension in the skeletal muscle, indi-
cating that AT1-mediated hypertension should be the main cause of fibrosis in the skeletal
muscle. Furthermore, the more expressive upregulation of fibrogenic genes in SHR myoblast
than WR myoblast after treatment with AngII (Fig 3A and 3B) corroborates this assumption.
There are several evidences showing that interfering TGFβR with signaling by AT1 signal-
ing is one of the mechanisms that organisms control fibrosis [12–14]. In order to verify the
influence of AT1 on the expression of fibrotic genes, we used myoblasts isolated from SHR,
once these cells are the main source to skeletal muscle regeneration after injury [42]. Our in
vitro study show a clear influence of AT1 on the expression of Tgfb1,Tgfbr2,and Smad3, and
fibrotic genes controlled by Col1a1 and Col3a1 genes (Fig 5), except for the profibrotic Ctgf,
which was upregulated after mirAT1a treatment. CTGF is a pleiotropic factor that under nor-
mal circumstances is involved in angiogenesis and cellular differentiation, but in pathological
conditions CTGF modulates, among others, wound healing and fibrosis [58–60]. Although
CTGF regulates such large biological activities, its gene expression is modulated mainly by
TGFß1 [61–63] but AngII can also induce TGFß1 expression independently [64]. Thus,
although AT1 signaling and TGF-ß1 receptor signaling have cross-talk, the knockdown of
AT1 with mirAT1a does not necessarily interrupt TGF-ß1 signaling and Ctgf expression.
Therefore, it seems that skeletal muscle fibrosis in hypertensive organisms follows the same
mechanism ones of the normotensive organisms, but more markedly.
Losartan, an angiotensin receptor antagonist, has been shown to be a good inhibitor of skel-
etal muscle fibrosis [14,65] and cardiac muscle fibrosis after injury [12,34]. Even losartan is a
FDA-approved drug and is widely used to treat hypertension, its oral use to treat skeletal mus-
cle fibrosis after injury can bring unnecessary undesired side effects, such as upper respiratory
infections, dizziness, hyperkalemia, and other symptoms [36–38]. Knockdown of AT1 with
Lv-miRNA or a similar vector system can avoid these side-effects since the vector is delivered
locally. To maintain the injected vectors in the muscle, avoiding vector leaking and spreading,
these lentivectors can be prepared with alginate hydrogel and injected directly into the muscle.
Just one injection can last more than two months of transgene expression in the muscle [66], a
sufficient time to heal the injured muscles, without targeting other tissues [39].
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Collectively, our in vivo and in vitro studies indicate that hypertension promotes more skel-
etal muscle fibrosis, and AngII-AT1a signaling is the main pathway of fibrosis in SHR, and
muscle fibrosis can be specifically treated with in loco injection of Lv-mirAT1a without affect-
ing other organs. Our studies also indicate that the skeletal muscle injury in hypertensive peo-
ple is prone to have more muscle fibrosis than in normotensive ones, thus contributing to the
development of muscle specific gene therapy vectors to improve muscle healing after injury
with less fibrosis.
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